When does PolyPeptide report earnings and what matters for PPGN.SW stock?

PolyPeptide reports on 12 Mar 2026 after markets. Investors should watch revenue, margin mix, guidance and neoantigen programme updates as these items will drive PPGN.SW stock volatility

What are the key valuation metrics for PPGN.SW stock?

Current price is CHF 25.10, EPS is -0.94 and trailing PE is -26.70. Price to sales is 2.48 and price to book is 2.78, which show mixed valuation relative to peers

What is Meyka AI’s near-term forecast for PPGN.SW stock?

Meyka AI's forecast model projects a yearly price of CHF 32.87, implying about +30.96% from CHF 25.10. Forecasts are model‑based projections and not guarantees

What risks should investors consider for PPGN.SW stock?

Main risks include continued negative EPS, inventory and working capital swings, and weaker contract demand. A cautious read of guidance could trigger downside in PPGN.SW stock

CH Stocks

Earnings due 11 Mar 2026 pre-market: PPGN.SW PolyPeptide AG (SIX) guidance key

ByHuzaifa Zahoor March 11, 2026March 11, 2026

We enter pre-market trading with PolyPeptide Group AG (PPGN.SW) at the centre of an earnings spotlight. The company reports after markets on 12 Mar 2026, and investors will parse revenue, margins and guidance for peptide CDMO demand. The stock trades at CHF 25.10 with a +2.66% move today and volume 67700.00. We summarise what the report can mean for PPGN.SW stock, valuation and near-term trading in Switzerland (SIX)